Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIM1 antisense RNA 1 (SIM1-AS1)
- Target
- SIM1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA (asRNA)
01
Overview
SIM1 antisense RNA 1 (SIM1-AS1) is a long non-coding RNA transcribed antisense to the SIM1 gene locus. Like other antisense RNAs, it is thought to regulate gene expression primarily at the transcriptional or post-transcriptional level, including potential cis-acting effects on the nearby SIM1 gene. The molecular mechanisms may involve alteration of chromatin state, interference with transcription, or modulation of mRNA stability or translation. While antisense lncRNAs are increasingly recognized as critical regulators in diverse biological processes and diseases, SIM1-AS1 itself currently has no well-established role as a therapeutic target or disease biomarker.
- Other names
- NR_187148.1
02
Mechanism of action
Not applicable for SIM1-AS1 itself. Broadly, drugs targeting asRNAs (generally synthetic antisense oligonucleotides) act through: mRNA degradation (RNase H mediated), Steric hindrance of translation, or Modulation of splicing (general for antisense RNA targets, not specific for SIM1-AS1).
03
Biological functions
Regulation of gene expression (typically in cis, affecting expression of the SIM1 gene or nearby loci)Epigenetic regulation (can modulate chromatin state at the locus)RNA-mediated interference (by formation of asRNA-mRNA duplexes leading to translation inhibition or mRNA degradation, general asRNA property)
04
Disease associations
No specific diseases have been directly attributed to SIM1-AS1 itself in available databases as of the current literature. However, dysregulation of antisense lncRNAs can be implicated in cancer, developmental disease, and epigenetic disorders in general
05
Safety considerations
None specific to SIM1-AS1. In general, challenges for targeting asRNAs include off-target effects, difficulty in specific delivery, and unpredictable epigenetic consequences
Beyond the preview
Go deeper on SIM1 antisense RNA 1 (SIM1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM1 antisense RNA 1 (SIM1-AS1).